BioCentury
ARTICLE | Company News

CHMP backs Luxturna, Lilly's migraine mAb, antibiotic Vabomere

September 21, 2018 9:45 PM UTC

EMA's CHMP Friday recommended several therapies for approval, including gene therapy Luxturna voretigene neparvovec, migraine mAb Emgality galcanezumab and antibiotic Vabomere meropenem/vaborbactam.

CHMP also confirmed its negative opinion for Exondys eteplirsen from Sarepta Therapeutics (NASDAQ:SRPT) for Duchenne muscular dystrophy...